Stragen
Lionel Lamy is a seasoned professional with extensive experience in the pharmaceutical and healthcare sectors. Currently serving as Responsable Régional des Relations Hospitalières Zone Sud at Stragen since February 2022, Lionel has previously held significant roles including Ingénieur Commercial Division Santé at aqua-tools and Hospital Sales Director for France at Bluefish Pharmaceuticals. Additional experience encompasses positions such as Key Account Manager for Zone Sud, Délégué Pharmaceutique, and commercial management in various companies. A graduate of Université de Limoges with multiple degrees, including DEUST Visite Medicale and DEUST ACPS in Commercial Pharmacy, Lionel's background combines sales expertise with academic knowledge in healthcare.
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.